Fig. 5From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosisComparison of the median decreases and cumulative decreases in TBIL levels between group A and group C and between group B and group D at different time points. a Median decrease in TBIL levels between group A and group C. b Cumulative decreases in TBIL levels between group A and group C. c Median decrease in TBIL levels between group B and group D. d Cumulative decreases in TBIL levels between group B and group D. Group A, liver failure patients treated with UCMSCs for more than 4 weeks (> 4 times); group C, liver cirrhosis patients treated with UCMSCs for more than 4 weeks (> 4 times); group B: liver failure patients treated with UCMSCs for less than or equal to 4 weeks (≤ 4 times); group D, liver cirrhosis patients treated with UCMSCs for less than or equal to 4 weeks (≤ 4 times). TBIL, total bilirubin. **P < 0.01Back to article page